ClinicalTrials.gg
Sign In

Telangiectasia, Hereditary Hemorrhagic clinical trials

The registry lists 106 studies for Telangiectasia, Hereditary Hemorrhagic across more than 10 countries. 24 are recruiting or about to start. 99 of them are mainly about Telangiectasia, Hereditary Hemorrhagic (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-13.

Get an email when these change. Save the Telangiectasia, Hereditary Hemorrhagic studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.

Watch these studies
See an example email

Example · made-up studies

Breast cancer · Recruiting: 2 came in, 3 changed

What changed in your saved searches, Oct 31 – Nov 6:

A study of drug A after surgery for early breast cancer

Came in · now Recruiting

Drug B with hormone therapy in advanced breast cancer

Changed

· Sites: 4 added, including Seoul and Busan

· Enrollment: 300 → 450 participants

Exercise during chemotherapy

Now Active, not recruiting

One email a week for all your saved searches. Stop any time.

Status

Completed
63
Recruiting
17
Active, not recruiting
7
Not yet recruiting
5
Status unknown
5
Terminated
4

Phase

Phase 2
32
Phase 1
15
Phase 3
9
Phase 4
2

Where

United States
29
France
27
United Kingdom
13
Canada
12
Germany
10
Netherlands
5

Who runs them

Hospices Civils de Lyon (20) · Imperial College London (13) · Unity Health Toronto (8) · University Hospital, Essen (8) · National Center for Research Resources (NCRR) (4) · Hospital Italiano de Buenos Aires (3) · University of California, San Diego (3) · Cure HHT (3)

What is being tested here

Drugs under test in Telangiectasia, Hereditary Hemorrhagic studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted

DrugOpenPhase 3All
Pazopanib113
Engasertib112
Nintedanib102
Topical Sirolimus101
Bevacizumab0210
Timolol003
Doxycycline002
Tacrolimus002
Pomalidomide002
Tranexamic Acid012

Drug classes tested here Tyrosine kinase inhibitors (TKIs) 2 open · Angiogenesis inhibitors 11

Coming up

1phase 3 study under way
6studies finish main data collection within a year

Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.

All 6

Who these studies take

Of the 17 Telangiectasia, Hereditary Hemorrhagic studies recruiting now, 14 (82%) set no upper age limit and 2 (12%) stop at 75 or younger. 6 (35%) take children under 18. 1 (6%) are for women only and 0 (0%) for men only; 3 (18%) take healthy volunteers.

Recruiting studies that take each age, of 17
AgeWomenMen
106 (35%)6 (35%)
1817 (100%)16 (94%)
3016 (94%)15 (88%)
4016 (94%)15 (88%)
5015 (88%)15 (88%)
6515 (88%)15 (88%)
7515 (88%)15 (88%)
8515 (88%)15 (88%)

Across all 106 studies, recruiting or not: 8% stop at 75 or younger and 4% at 65; 25% take children; 2% are for women only and 0% for men only; 13% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.

How long Telangiectasia, Hereditary Hemorrhagic studies take

Of 14 phase 2 interventional studies under Telangiectasia, Hereditary Hemorrhagic, half reached primary completion within 36 months of starting, counting those still running.

Start to primary completionEvery sponsorIndustryNon-industry
Phase 236 mo29–55 · 14 studies——
Observational56 mo36–184 · 23 studies——

Each figure is the month by which half the studies had reached primary completion, with the range in which the middle half did. Studies still running count until their last registry update; studies that stopped early are left out. Phase 1 includes early phase 1; observational means prospective or not stated, as retrospective and cross-sectional studies date a window of data rather than a study. How these figures are worked out

What changed recently

From the registry's own updates since Oct 15, 2026.

Started recruiting1

Newly registered1

Studies

Recruiting first, then most recently updated. Showing 50 of 106. Browse all 106 → or search them.